Business
BullFrog AI and Sygnature Discovery Announce Official Sales Launch of BullFrog Data Networks™ to Global Biopharma Clients
Sales launch marks pivotal commercial milestone, unlocking up to $30 million in potential revenue through 2028GAITHERSBURG, Md., Sept. 25, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its collaboration with Sygnature Discovery, a leading con
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"image","alt":"BullFrog AI Holdings, Inc.","displaySize":"","headline":null,"caption":"BullFrog AI Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cckXAhHY1jCBABonzk6CjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e","width":300,"height":73}},"lazy":false},{"type":"text","content":"Sales launch marks pivotal commercial milestone, unlocking up to $30 million in potential revenue through 2028","length":110,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Sept. 25, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its collaboration with Sygnature Discovery, a leading contract research organization (CRO) specializing in drug discovery, has entered the commercial phase. With the formal sales kickoff on September 12, BullFrog AI’s proprietary BullFrog Data Networks™ platform is now actively being introduced to Sygnature’s global client base, representing a revenue opportunity estimated at $15–$30 million through 2028.","length":766,"tagName":"p"},{"type":"text","content":"The commercial rollout follows the completion of training for Sygnature’s global business development team, equipping them to market BullFrog Data Networks™ as part of Sygnature’s industry-leading portfolio of drug discovery solutions. By leveraging Sygnature’s extensive relationships across the biopharma sector, BullFrog AI is looking to accelerate adoption of its pioneering platform at scale.","length":397,"tagName":"p"},{"type":"text","content":"“The official kickoff of sales through Sygnature marks a potential inflection point for BullFrog AI,” said Vin Singh, Founder and CEO of BullFrog AI. “We are now positioned to realize the revenue potential of this collaboration and deliver our AI-driven data insights platform to biopharma innovators globally. Our shared commitment to accelerating drug discovery will create significant...